Catalyst Biosciences, Inc.

Develops therapeutics for hemophilia and inflammatory diseases

Transaction Summary

  • Completed reverse merger with Targacept in August 2015
  • Catalyst is the surviving public entity now trading on the NASDAQ as "CBIO"
  • Lead product, a Factor VIIa drug candidate for hemophilia, has successfully completed Phase I trials
  • Catalyst is well-capitalized to advance its hemophilia drug into pivotal clinical trials